Biologics Contract Development Market
Global Biologics Contract Development Market: Overview
Biologics contract development is the comprehensive outsourcing service that manufactures biotechnology, pharmaceutical, and medical devices supporting biomaterials under the label of another company.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
Global Biologics Contract Development Market: Growth Factors
Some of the significant factors that boost the global biologics contract development market are the surge in the adoption of advanced techniques for biological production, outsourcing the research & development tasks by pharma companies, and a well-suited environment for performing clinical trials. The surge in merger and collaboration activities increases the outsourcing of pharma and biopharma companies to expand in the developed and developing countries.
For instance, Thermo Fisher Scientific Inc. acquired Brammer Bio, a leader in contract development of cell and gene therapy, to empower its portfolio in gene therapy.
There has been a surge in diseases like cancer, neurology disorders, cardiovascular disorder, gynecological disorders, and ophthalmic disorders in recent years. The healthcare CDMOS emerged as a savior in patient care and many pharma leaders are making their contribution in inventing novel therapies for the efficient treatment of these diseases.
The increase in research and development investment for future advancements in technology fuels the market to grow significantly with high rates.
Biological contracts gradually shift to single-use bioreactors to facilitate the reduction in upfront costs and enhance manufacturing flexibility. Improved flexibility in manufacturing productivity increases the supply of biology and thus drives the global biologics contract development market.
Global Biologics Contract Development Market: Segmentation
The global biologics contract development market can be segmented into the source, product, disease, and region.
By source, the market can be segmented into mammalian, microbial, and others. The mammalian segment has the largest market share and is forecasted to witness significant growth rate in the coming years. The growth can be attributed to the usage of mammalian cells for protein synthesis to produce accurate post-transnational mammalian protein. Chinese mammalian cells are preferred the most for protein therapeutics and development for CMO cells.
The microbial cell segment is expected to witness a high growth rate over forecast years. The microbial cell lines are majorly used in the production of hormones, enzymes, cytokines, and others.
By product, the market can be segmented into cell line development and process development.
The process development segment holds the largest share in the global biologics contract development market. The process development can further be segmented into upstream, downstream, and others.
The upstream process includes the choosing of the right cell line, bioreactor system, operating dimensions, and culture medium.
The downstream process includes the testing and purification of a fermented medium having an inoculum. Many qualitative assessments like pharmaceutical analysis, physicochemical characterization, packaging, and validating polishing are included in the downstream process segment.
By disease, the market can be segmented into oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others.
The oncology segment holds the largest market share.
The immunology segment is expected to witness high growth rate over the forecast years. There are growing cases of immune system dysfunction all over the world.
Global Biologics Contract Development Market: Regional analysis
North America has the largest share in the global biologics contract development market. The growth in the region can be attributed to the surge in research & development investments and the presence of global players locally. The growth of contract development (CDO) also attributes to the increase in outsourcing of various tasks & clinical trials and thus boosts the regional market.
Asia Pacific is expected to witness high growth rate over the forecast years. The growth can be attributed to the amendments done to change the evaluation standard of clinical trials and increased investment to improve the technology by the prominent industry players.
Global Biologics Contract Development Market: Competitive Players
Some of the prominent players in the global biologics contract development market are WuXi Biologics, AGC Biologics, Genscript Biotech Corporation, Abzena Ltd., SE Thermo Fisher (Patheon), Bionova Scientific, LakePharma, STC Biologics, Inc., Hansen, Fujifilm Diosynth Biotechnologies, KBI Biopharma, Boehringer Ingelheim BioXcellence, and AGC Biologics.
Global Biologics Contract Development Market: Regional Segment Analysis
What Reports Provides